Andreas Abt
@AndreasAbt1
Followers
5K
Following
78
Media
212
Statuses
4K
Founder OncologyPipeline. 20+ years in Oncology
Madrid
Joined September 2011
Bayer looks to clinical validation for $1.5bn Vividion deal | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
0
0
0
12 years on, Jakafi faces serious JAK competition https://t.co/MXX2ynQM1W $INCY $GSK
oncologypipeline.com
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
0
1
0
Bristol seeks novelty in TIGIT -> all you need to know about #CD96 from @JacobPlieth @ApexOnco
https://t.co/xGKITrodsi
oncologypipeline.com
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
0
0
0
Moderna moves on swiftly with its neoantigen immunotherapy | ApexOnco - Clinical Trials news and analysis - 2nd phase III study announced
oncologypipeline.com
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
0
0
0
Finding the USP in synthetic lethality https://t.co/CKtO5B3hFp Where is @AstraZeneca?
oncologypipeline.com
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.
0
0
0
$BCYC pursues accelerated pathway while $SGEN's similarly acting ADC is already fully approved. What could possibly go wrong? Via @ApexOnco -> https://t.co/fBIyTgLgfE (with table of other Nectin-4 projects)
oncologypipeline.com
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
5
2
25
No end in sight for antibody-drug conjugate enthusiasm | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
0
0
0
World Lung 2023 – Flaura2 leaves a gap open for J&J | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
0
0
0
Tivdak success could make life even harder for Iovance | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
1
0
0
ESMO 2023 preview – conjugates, bispecifics and more | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
0
0
0
Roche stakes its KRAS claim | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
0
0
0
Point looks to make a year-end Splash | ApexOnco - Clinical Trials news and analysis
oncologypipeline.com
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
0
0
0
Here’s what you need to know about the latest slate of biotechs vying for a spot on Wall Street. https://t.co/CY6RKr79V8
endpoints.news
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. Last week was a busy one for biotech IPOs, with five more companies ...
0
1
0
Surprised our pandemic response was weak? We've been underfunding our institutions. “Nothing turns out to be so oppressive and unjust as a feeble government” — Edmund Burke 👉 https://t.co/LyaxnMGsdY
15
32
164
#Coronavirus: la OMS fija pautas a los congresos médicos 'postpandemia'
0
5
1
After 27 extraordinary months with @AstraZeneca, back to Paris to lead @GustaveRoussy as its new General Director after today appointment by Minister of Health @agnesbuzyn. Looking forward to continuing the journey to improve the life of patients https://t.co/v2O60hkarR
66
69
581
2 years ago $CLVS stock scraped $100 a share -- it closed yesterday at $3.93 as $AZN/$MRK and $GSK had a showdown in frontline ovarian.
2
3
12
The TITAN trial tested whether the addition of apalutamide, an androgen receptor blocker, to androgen-deprivation therapy might improve radiographic (including MRI-detected) progression–free survival and overall survival. See the results: https://t.co/vEkZwXALsa
#ASCO19 #oncology
10
29
59
"5 Key Elements of Chinese Biopharma’s ‘Cambrian Explosion’ " https://t.co/vyPmUH9zwx by @fle864 on @LinkedIn
linkedin.com
The explosion of activity in Chinese biopharma since the initiation of the CFDA (China Food and Drug Administration) reform in 2015 is shaping the industry on a global level. The first wave of new...
2
16
27
Kapil Dhingra at FNIH Biomarkers consortium develops the concept of targeted payload delivery beyond ADC
0
4
17